G207

About Treovir

Treovir is a private, pre-revenue biotech advancing G207, a targeted oncolytic immunotherapy for recurrent pediatric brain tumors. The therapy demonstrated improved survival with no serious side effects in a Phase 1 study and has now entered a pivotal Phase 2 trial in 2024, supported by FDA Fast Track and orphan drug designations. With a seasoned leadership team deeply experienced in oncolytic virology and brain tumor research, Treovir is positioned to address a critical unmet need in pediatric oncology where there are currently zero FDA-approved therapies.

Therapeutic Areas